Inhibition of protein–protein interactions using designed molecules
- 27 July 2009
- journal article
- review article
- Published by Royal Society of Chemistry (RSC) in Chemical Society Reviews
- Vol. 38 (12) , 3289-3300
Abstract
Although many cellular processes depend upon enzymatic reactions, protein–protein interactions (PPIs) mediate a large number of important regulatory pathways and thus play a central role in disease development. In order to understand and selectively inhibit cellular signalling pathways, there is a pressing need for small molecules that target PPIs, particularly in the context of pharmaceutical development. This tutorial review will introduce the relevance of PPIs to chemical biology and highlight the key challenges in designing inhibitors. Some of the successes using conventional approaches to the identification of small-molecule PPI inhibitors will be highlighted, and also the reasons why these approaches have not always proven successful. Several general approaches tailored to particular protein topologies are emerging for the design of scaffolds that inhibit PPIs—these will form the major content of this review. Finally a summary of the challenges to be faced in developing inhibitors of PPIs into drug leads and how these challenges may differ from those encountered with enzyme-like targets will be given.Keywords
This publication has 69 references indexed in Scilit:
- Principles of Protein−Protein Interactions: What are the Preferred Ways For Proteins To Interact?Chemical Reviews, 2008
- Reaching for high-hanging fruit in drug discovery at protein–protein interfacesNature, 2007
- Strategies for Targeting Protein–Protein Interactions With Synthetic AgentsAngewandte Chemie International Edition, 2005
- An inhibitor of Bcl-2 family proteins induces regression of solid tumoursNature, 2005
- Chemical genetics to chemical genomics: small molecules offer big insightsChemical Society Reviews, 2005
- In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2Science, 2004
- Short constrained peptides that inhibit HIV-1 entryProceedings of the National Academy of Sciences, 2002
- Molecular Recognition of Protein−Ligand Complexes: Applications to Drug DesignChemical Reviews, 1997
- Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation DomainScience, 1996
- A Hot Spot of Binding Energy in a Hormone-Receptor InterfaceScience, 1995